TL-532 / Tollys - LARVOL DELTA

A Chemically Defined TLR3 Agonist with Anticancer Activity. (PubMed, Oncoimmunology) - "In addition, in immunodeficient mice lacking formylpeptide receptor-1 (FPR1), TL-532 was able to restore the response of orthotopic subcutaneous fibrosarcoma to immunogenic chemotherapy. Altogether, these findings may encourage further development of TL-532 as an immunotherapeutic anticancer agent."

IO biomarker • Journal • Bladder Cancer • Fibrosarcoma • Genito-urinary Cancer • Melanoma • Oncology • Sarcoma • Solid Tumor • Urothelial Cancer

TL-532, a novel specific Toll-like receptor 3 agonist rationally designed for targeting cancers: discovery process and biological characterization. (PubMed, Microb Cell) - "TL-532 induces inflammation in murine RAW264.7 myeloid macrophages, in human NCI-H292 lung cancer cells, and it promotes immunogenic apoptosis in tumor cells in vitro and ex vivo without toxicity towards normal primary cells. In conclusion, we identified a novel TLR3 agonist called TL-532 that has promising anticancer properties."

Journal • Lung Cancer • Oncology • Solid Tumor • IFIH1 • TLR7 • TLR8 • TLR9

The specific TLR3-agonist TL-532 induces life-long anti-tumor autovaccination, cross-immunity against unrelated cancers and reverses resistance to immune checkpoint inhibitors (AACR 2022) - "We identified TL-532 as spearhead of a new rationally designed TLR3-agonist family. In monotherapy, it demonstrated substantial tolerance and promising anti-cancer and autovaccinal activity, which included unrelated cancers. TL-532 also demonstrated its remarkable ability to overcome ICI tumor-resistance, thus increasing the clinical landscape for ICI combination treatment."

Checkpoint inhibition • IO biomarker • Bladder Cancer • Genito-urinary Cancer • Oncology • Osteosarcoma • Sarcoma • Solid Tumor • Urothelial Cancer • CCL2 • CCL22 • CXCL10 • CXCL9 • IFNA1 • IFNG

AACR 2022: Tollys releases new preclinical data demonstrating lifelong potent anti-tumor immunity of TL-532 (PharmiWeb) - "Tollys...announces that it will release the latest preclinical developments of TL-532 at the American Association for Cancer Research (AACR) Annual Meeting 2022....In vivo activity of TL-532 led to substantial tumor growth inhibition (88%) and delay (370%), translating into 35%....Remarkably, 54% (6/11) of the mice autovaccinated against bladder cancer also demonstrated cross-immunity against an unrelated and poorly immunogenic, syngeneic osteosarcoma cancer cell model (LM8)."

Preclinical • Bladder Cancer • Genito-urinary Cancer • Oncology • Solid Tumor • Urothelial Cancer